MAM-1001-1/Inhaleen is an inhalable formulation of Carragelose, which is a polymer extracted from red seaweed that forms a protective layer on mucosal surfaces. Carragelose has been well-established as broad-spectrum virus-blocking compound used in a marketed OTC product portfolio for the treatment of viral respiratory infections and has been shown to effectively inhibit a wide range of respiratory viruses. Inhaleen is intended to treat viral respiratory infections of the upper and lower respiratory tract. By inhaling Carragelose, it is possible to utilize its broadly active virus-blocking effect in an area that could not previously be reached with a nasal spray.
The goal is to develop inhalable Carragelose that can be used with standard inhalation devices, both in the hospital and at home by the patient. This inhalable form of Carragelose can be used to treat all areas from the throat to the bronchi to the lungs and protect against progressive viral infection.